Reviva Pharmaceuticals Holdings, Inc. expected to post a loss of 28 cents a share - Earnings Preview

Reviva Pharmaceuticals Holdings

11/08/2023 13:09

* Reviva Pharmaceuticals Holdings, Inc.  RVPH.OQ 
 RVPH.O  is
expected to show no change in quarterly revenue when it reports 
results on August 14 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Reviva
Pharmaceuticals
Holdings, Inc. is for a loss of 28 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Reviva
Pharmaceuticals Holdings, Inc. is $16​, above​ its last closing
price of $4.32. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.32       -0.32      -0.30     Beat    7.7
 Dec. 31 2023  -0.19       -0.22      -0.38     Missed  -72.7
 Sep. 30 2022  -0.28       -0.29      -0.18     Beat    37.2​
 Jun. 30 2022  -0.36       -0.35      -0.29     Beat    17.1
 ​​Mar.        -0.28       -0.28      -0.40     Missed  -42.9
 31 2022                                                
 Dec. 31 2021  -0.25       -0.25      -0.22     Beat    12​
 Sep. 30 2021  -0.24       -0.23      -0.12     Beat    48.9
 Jun. 30 2021  -0.24       -0.24      -0.12     Beat    50
 This summary was machine generated August 11 at 12:09 GMT.  All
figures in US dollars  unless otherwise stated